EUCTR2013-003439-31-GB进行中（未招募）1 期
A 24-week, double blind treatment and 24-week follow-up, randomised, multicenter, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass and physical performance in patients after surgical treatment of hip fracture.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 245
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Must have had surgical fixation or arthroplasty for a fracture of the proximal femur as confirmed by radiography
- •- Must be able to complete a 4 m gait speed test
- •- Must weigh at least 35 kg.
- •- Must have completed surgical wound healing.
- •Other protocol-defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 245
排除标准
- •Must not have history of any other lower limb fractures in the past 6 months
- •Must not have certain cardiovascular conditions
- •Must not have a chronic active infection (e.g. HIV, hepatitis B or C, etc)
- •Must not have used high-dose corticosteroid medications for at least 3 months in the past year
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of Bimagrumab in patients after hip fracture surgeryPatients with muscle wasting (atrophy) after hip fracture surgery and subsequent postsurgical rehabilitationMedDRA version: 20.0Level: LLTClassification code 10028371Term: Muscular wasting and disuse atrophy, not elsewhere classifiedSystem Organ Class: 100000004859MedDRA version: 20.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-003439-31-DEovartis Pharma Services AG245
进行中（未招募）
1 期
Study of efficacy and safety of Bimagrumab in patients after hip fracture surgeryPatients with muscle wasting (atrophy) after hip fracture surgery and subsequent postsurgical rehabilitationMedDRA version: 20.0Level: LLTClassification code 10028371Term: Muscular wasting and disuse atrophy, not elsewhere classifiedSystem Organ Class: 100000004859MedDRA version: 20.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-003439-31-ATovartis Pharma Services AG245
进行中（未招募）
1 期
Study of efficacy and safety of Bimagrumab in patients after hip fracture surgeryPatients with muscle wasting (atrophy) after hip fracture surgery and subsequent postsurgical rehabilitationMedDRA version: 20.0Level: LLTClassification code 10028371Term: Muscular wasting and disuse atrophy, not elsewhere classifiedSystem Organ Class: 100000014468MedDRA version: 20.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-003439-31-CZovartis Pharma Services AG250
进行中（未招募）
1 期
Study of efficacy and safety of Bimagrumab in patients after hip fracture surgeryPatients with muscle wasting (atrophy) after hip fracture surgery and subsequent postsurgical rehabilitationMedDRA version: 20.0Level: LLTClassification code 10028371Term: Muscular wasting and disuse atrophy, not elsewhere classifiedSystem Organ Class: 100000014468MedDRA version: 20.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-003439-31-HUovartis Pharma Services AG245
进行中（未招募）
1 期
Study of efficacy and safety of Bimagrumab in patients after hip fracture surgeryPatients with muscle wasting (atrophy) after hip fracture surgery and subsequent postsurgical rehabilitationMedDRA version: 20.0Level: LLTClassification code 10028371Term: Muscular wasting and disuse atrophy, not elsewhere classifiedSystem Organ Class: 100000004859MedDRA version: 20.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2013-003439-31-BEovartis Pharma Services AG245